Maqui Berry Extract for Dry Eye Lacrimal Secretion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Excessive use of visual display terminals (VDTs) leads to decreased lacrimal secretion and increased oxidant stress, causing dry eye symptoms, with existing remedies providing only temporary relief.

Innovation Solution

A prophylactic and therapeutic agent containing maqui berry extract or delphinidin glycoside, which inhibits the deterioration of lacrimal secretory ability and suppresses radical oxygen generation in the lacrimal gland tissue, effectively addressing dry eye symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If artificial tears are used to replace deficient lacrimal liquid, then temporary relief from dry eye symptoms is achieved, but the underlying lacrimal secretion dysfunction remains unresolved

Engineering Contradiction:

Improvetemporary relief from dry eye symptomsVSAvoidduration of symptom relief

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent converts the harmful oxidant stress that causes lacrimal gland dysfunction into a beneficial treatment target by using antioxidants (maqui berry extract, delphinidin glycoside) to neutralize the oxidant stress, thereby restoring normal lacrimal secretion function and providing long-term relief from dry eye symptoms

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent enables the lacrimal gland to restore its own function by eliminating oxidant stress through antioxidant administration, allowing the gland to resume normal lacrimal secretion without continuous external intervention with artificial tears

Inventive Principle:

Principle #25Self-service

2Reliability

If lacrimal puncta are closed to retain existing lacrimal liquid, then temporary moisture retention is achieved, but the root cause of reduced lacrimal secretion is not addressed

Engineering Contradiction:

Improvetemporary moisture retentionVSAvoidreduced lacrimal secretion

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful oxidant stress in the lacrimal gland into a beneficial treatment target by administering antioxidants that neutralize the oxidant stress, thereby restoring normal lacrimal secretion function and eliminating the need for punctal occlusion

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent applies preliminary antioxidant treatment to prevent oxidant stress-induced damage to the lacrimal gland before severe dysfunction occurs, thereby maintaining normal lacrimal secretion function and preventing the development of chronic dry eye conditions

Inventive Principle:

Principle #10Preliminary action

3Productivity

If excessive VDT viewing continues to meet work demands, then productivity is maintained, but oxidant stress increases and lacrimal secretion deteriorates

Engineering Contradiction:

Improvework productivityVSAvoidoxidant stress in lacrimal gland

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful oxidant stress generated during prolonged VDT viewing into a treatable condition by using antioxidants (maqui berry extract, delphinidin glycoside) to neutralize the oxidant stress, thereby protecting the lacrimal gland while allowing continued productivity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces antioxidants as intermediary substances that mediate between the harmful oxidant stress from VDT viewing and the lacrimal gland tissue, protecting the gland from damage while allowing normal work activities to continue

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The maqui berry extract or delphinidin glycoside-based agent significantly enhances lacrimal secretion and reduces radical oxygen species in the lacrimal gland, providing sustained relief from dry eye symptoms.

Implementation Method 1

maqui berry extract or delphinidin glycoside suppresses radical oxygen generation in the lacrimal gland tissue

Methodology Applied

Scientific EffectAntioxidant activity: Oxidation

Data Source

PatentUS11033566B2Method of improving lacrimal secretion for dry eye treatment using maqui berry extract

Publication Date: 2021.06.15 ORIZA YUKA KK

AI summary

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.